Xencor Inc (XNCR) Stock
XNCR has an Alpha Score of 48 out of 100 (weak), computed on Nov 8, 2026 from 2 of 4 sub-scores. 4 of the hedge funds AlphaScala tracks reported XNCR in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Millennium Management's at $13.74M.
What is XNCR's Alpha Score?
How it works →Alpha Score of 48 reflects weak overall profile with strong momentum, poor quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 8, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own XNCR?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Millennium Management Israel Englander | 854K | $13.74M | +40% |
| Citadel Ken Griffin | 191K | $3.07M | -49% |
| Point72 Steve Cohen | 72K | $1.15M | NEW |
| D.E. Shaw David Shaw | 50K | $812.6K | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →What are XNCR's key statistics?
Key statistics as of Nov 8, 2026
How does XNCR's valuation compare with the Healthcare sector?
| Metric | XNCR | Healthcare median | Companies in median |
|---|---|---|---|
| Net margin | -155.59% | 3.60% | 175 |
| Return on equity | -28.66% | 2.93% | 201 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 11, 2026). P/E excludes loss-making companies.
XNCR price chart
Powered by TradingViewWhat does Xencor Inc do?
Xencor Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of engineered monoclonal antibodies and antibody therapeutics. Powered by its proprietary XmAb protein engineering platform, Xencor designs drug candidates optimized for enhanced efficacy and safety profiles to treat patients with cancer, asthma, allergic diseases, and autoimmune conditions. The company maintains a broad pipeline, with more than 20 programs in clinical testing and numerous others in preclinical development. Notably, three XmAb medicines are currently marketed by strategic partners, enabling milestone payments, royalties, and collaborative advancements. Xencor focuses on expanding the therapeutic potential of antibodies through innovative protein engineering from the ground up, addressing severe diseases where conventional treatments fall short. Founded in 1997 and headquartered in Monrovia, California, Xencor plays a key role in the biotechnology sector by advancing next-generation biologics for unmet medical needs.